Main Line biotech firm raises $40M in Series A round to advance new high blood pressure treatment

The company was founded in 2020.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.